Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck MRK-0.87%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

The NFL credited a drop in the number of concussion cases this season with advances in helmet technology but players said it ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...